List of Excipients in Branded Drug ZEMPLAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	ZEMPLAR	paricalcitol	0074-4314	ALCOHOL
AbbVie Inc	ZEMPLAR	paricalcitol	0074-4314	BUTYLATED HYDROXYTOLUENE
AbbVie Inc	ZEMPLAR	paricalcitol	0074-4314	FERRIC OXIDE RED
AbbVie Inc	ZEMPLAR	paricalcitol	0074-4314	FERRIC OXIDE YELLOW

Zemplar Excipient Strategy and Commercial Opportunities for Paricalcitol

Last updated: August 27, 2026

Zemplar is an established paricalcitol product for secondary hyperparathyroidism associated with chronic kidney disease. Its original U.S. market exclusivity has expired, and commercial value now depends on manufacturing cost, bioequivalence execution, hospital supply reliability, formulation differentiation, and access to dialysis-related purchasing channels. The strongest excipient opportunities are in low-dose oral capsule uniformity, injectable solvent reduction, ready-to-use hospital presentations, pediatric delivery, and supply-chain control.

What is Zemplar and which dosage forms are commercially relevant?

Zemplar contains paricalcitol, a synthetic vitamin D analog that reduces parathyroid hormone production while limiting the calcium and phosphorus increases associated with older vitamin D therapies. The FDA-approved product has been marketed in oral capsules and an injectable presentation for intravenous use in patients with chronic kidney disease receiving dialysis (FDA, 2023a; FDA, 2023b).

Attribute	Zemplar capsules	Zemplar injection
Active ingredient	Paricalcitol	Paricalcitol
Primary use	Secondary hyperparathyroidism in CKD	Secondary hyperparathyroidism in CKD
Administration	Oral	Intravenous
Typical strengths	1, 2 and 4 mcg	2 mcg/mL and 5 mcg/mL presentations have been approved
Main commercial channel	Specialty pharmacy, nephrology, dialysis-related prescribing	Dialysis centers, hospitals and institutional pharmacies
Regulatory category	Small-molecule drug	Small-molecule sterile injectable
Biosimilar pathway	Not applicable	Not applicable
Core differentiation	Capsule fill uniformity, dissolution and patient convenience	Sterility, solvent tolerability, container closure and ready-to-use handling

Paricalcitol is a low-dose, high-potency compound. That makes excipient selection important because a small change in blend uniformity, fill weight, adsorption, or dissolution can affect product performance.

What excipients are used in Zemplar formulations?

The approved Zemplar capsule and injection labels identify different formulation strategies. The capsule uses a soft-gelatin-type presentation with a lipid or oily fill system and capsule-shell components. The injection uses a solvent system containing propylene glycol and ethanol in water for injection (FDA, 2023a; FDA, 2023b).

Zemplar capsule excipient architecture

The capsule formulation uses excipients associated with soft-gelatin delivery, including gelatin, glycerin, titanium dioxide, coloring agents and an oily vehicle. Depending on the strength and market presentation, the capsule shell may use colorants to distinguish dose levels. The formulation objective is to solubilize or disperse a microgram-level dose while maintaining content uniformity and acceptable dissolution.

The relevant excipient functions are:

Excipient function	Commercial purpose	Primary development risk
Lipid or oily fill vehicle	Solubilizes or distributes paricalcitol	Oxidation, viscosity and fill-weight variability
Gelatin shell	Provides unit-dose containment	Cross-linking, brittleness and dissolution delay
Glycerin or plasticizer	Controls capsule flexibility	Migration and shell mechanical changes
Titanium dioxide	Opacifies the capsule	Regulatory restrictions in some jurisdictions
Colorants	Differentiates strengths	Market-specific regulatory and supply constraints

A generic developer should not treat the capsule shell as a cosmetic component. Shell composition can affect disintegration, dissolution, moisture transfer and stability. Gelatin cross-linking is particularly relevant for long-term storage and for products exposed to elevated temperature or humidity.

Zemplar injection excipient architecture

The injectable product uses water for injection with propylene glycol and ethanol as cosolvents. These solvents help maintain paricalcitol in solution at a low concentration but create handling and tolerability considerations for hospitals and dialysis providers (FDA, 2023b).

Injectable component	Function	Commercial implication
Propylene glycol	Cosolvent	Supports solubility but increases excipient-load concerns
Ethanol	Cosolvent	Helps maintain solution stability and may affect tolerability and handling
Water for injection	Sterile vehicle	Requires validated sterile manufacturing and container closure
Glass or polymer container	Primary package	Must control adsorption, leachables and extractables

The injectable formulation is less suitable for casual reformulation than the capsule because changes in solvent ratio can alter solubility, pH, precipitation behavior, sterilization compatibility and extractables. A materially different injectable formulation may require a more complex regulatory strategy than a conventional abbreviated new drug application.

Which excipient strategies offer the best commercial opportunities?

The highest-value strategy is to improve handling or manufacturing economics without creating a regulatory equivalence problem.

1. Optimize low-dose capsule content uniformity

Paricalcitol capsules contain microgram quantities of active ingredient. The formulation must prevent segregation and ensure consistent dosing across the batch. Commercially useful approaches include:

• pre-dissolving or highly dispersing paricalcitol in a controlled lipid vehicle;
• using a high-shear premix before capsule filling;
• controlling viscosity to reduce fill-weight variation;
• selecting antioxidants for the lipid phase where justified;
• using in-process near-infrared or validated assay controls;
• minimizing active adsorption to manufacturing equipment.

The main opportunity is a robust, low-cost formulation with reduced batch rejection and stable dissolution. A new excipient combination is unlikely to create durable market exclusivity by itself, but it can reduce cost of goods and improve supply reliability.

2. Develop a lower-solvent injectable formulation

The current solvent system creates an opportunity for a hospital-focused product with a reduced propylene glycol or ethanol burden. Potential approaches include:

• alternative cosolvent systems;
• surfactant-assisted aqueous solubilization;
• cyclodextrin-based solubilization;
• concentrated ready-to-use presentations;
• prefilled syringes or single-dose vials;
• lower-volume administration formats.

Each approach carries material development risk. Cyclodextrins, surfactants and alternative solvents introduce new toxicology, compatibility and regulatory questions. The commercial case is strongest where the product can reduce preparation steps, minimize dosing errors or improve use in patients who are sensitive to solvent exposure.

3. Offer a ready-to-use dialysis presentation

Dialysis centers value products that reduce preparation time and standardize dosing. A ready-to-use vial or prefilled syringe could compete on workflow rather than active-ingredient differentiation.

Relevant features include:

• terminally labeled concentration;
• low dead volume;
• tamper-evident packaging;
• barcoded dose identification;
• compatibility with common dialysis workflows;
• minimized need for dilution;
• single-dose packaging with low residual waste.

The commercial benefit would be greatest if the presentation is supported by reliable supply and competitive contract pricing. Device and container-closure claims may provide more practical differentiation than the excipient composition alone.

4. Create an oral liquid or sprinkle-compatible product

Zemplar capsules are not optimized for patients who cannot swallow capsules. A pediatric or dysphagia-oriented formulation could target:

• pediatric CKD patients;
• patients receiving enteral nutrition;
• patients with swallowing limitations;
• dialysis centers that need flexible dose titration.

An oral solution, suspension or sprinkle-compatible product would require careful attention to dose uniformity at very low concentrations, adsorption to dosing devices, light sensitivity, microbial control and taste masking. Because paricalcitol is potent, the product would need a highly reliable dosing device. A 505(b)(2) strategy may be relevant for a materially different dosage form, while a conventional generic pathway would generally be more constrained by the reference product’s dosage form and labeling.

5. Replace animal-derived capsule materials

A plant-based or non-gelatin capsule could address procurement requirements in selected markets. The tradeoff is technical: non-gelatin shells may have different moisture transmission, mechanical strength, thermal behavior and dissolution profiles.

This opportunity is more likely to support regional or institutional differentiation than a broad premium price. It could be valuable for government tenders, hospital systems with excipient policies, or markets where gelatin source is commercially sensitive.

How strong is the patent estate for Zemplar?

Zemplar is an old small-molecule product with expired primary exclusivity. The commercial barrier is therefore regulatory execution and supply economics rather than a strong remaining composition-of-matter patent position.

IP category	Zemplar relevance	Commercial assessment
Paricalcitol composition patent	Historically central	Expected to be expired or commercially exhausted
Original capsule formulation	Historically relevant	Limited current barrier to generic entry
Injectable formulation	Potentially relevant to historical products	Any remaining enforceable claim requires jurisdiction-specific verification
Method-of-use patents	May cover CKD dosing or treatment methods	Enforcement and listing relevance are limited compared with product patents
Device or packaging patents	Could support ready-to-use products	More relevant to differentiated follow-on products
Manufacturing know-how	Blend, fill, sterilization and container closure	Practical barrier, not necessarily public exclusivity
Trade secrets	Process controls and stability methods	Can protect cost and quality advantages

FDA Orange Book status should be reviewed for the specific reference-listed drug and dosage form before filing or licensing. Patent numbers, expiration dates and any pediatric-extension dates should be taken from the current Orange Book record rather than historical product literature (FDA, 2024a).

When did Zemplar lose exclusivity and when can generics launch?

Zemplar’s commercial exclusivity is long past the period associated with its original FDA approval. The FDA approved paricalcitol capsules in the late 1990s, and the injectable product followed as an established CKD therapy. Any current generic launch analysis should focus on listed patents, regulatory approval status, manufacturing capacity and procurement contracts rather than original market exclusivity.

A generic sponsor typically has four relevant certification options under Hatch-Waxman:

Certification	Meaning for paricalcitol
Paragraph I	No relevant patent information is listed
Paragraph II	Listed patents have expired
Paragraph III	Generic approval is sought after listed patent expiration
Paragraph IV	Listed patent is challenged as invalid, unenforceable or not infringed

For an old small-molecule product, Paragraph II or Paragraph III filings are more commercially probable unless a later-listed formulation or method patent remains relevant. A Paragraph IV filing would create litigation risk only if a qualifying patent is listed and the sponsor has a noninfringement or invalidity position.

What patent litigation and settlement issues affect Zemplar?

No high-value, current exclusivity barrier is apparent from the age of the product. Historical litigation involving paricalcitol should be separated from present-day market risk. The key legal questions are:

1. Whether any Orange Book-listed patent remains unexpired for the targeted dosage form.
2. Whether a generic formulation uses the same or a materially different excipient system.
3. Whether the proposed label overlaps any surviving method-of-use claim.
4. Whether an injectable formulation creates new formulation or container-closure claims.
5. Whether a license or supply agreement restricts a particular manufacturer or territory.

A formulation that changes the solvent system, dosage form or delivery device could avoid a legacy patent but create a new patent estate for the follow-on sponsor. Such patents would be narrower than a composition patent and more vulnerable to design-around strategies.

What is the FDA regulatory status of Zemplar?

Zemplar is an FDA-approved small-molecule product, not a biologic. Biosimilar risk is therefore not relevant. Competitive products enter through the abbreviated new drug application pathway when they can demonstrate pharmaceutical equivalence and bioequivalence to the reference product.

The regulatory pathway depends on the dosage form:

Capsules

A conventional generic capsule can generally rely on the reference product if it matches the required dosage form, strength and route and satisfies FDA bioequivalence and quality requirements. Formulation differences may be acceptable, but they cannot compromise pharmaceutical equivalence, product performance or labeling requirements.

Injection

An injectable generic faces stricter chemistry, manufacturing and controls requirements. The sponsor must demonstrate sterility assurance, particulate control, container-closure integrity, impurity control, solvent compatibility and stability. A materially changed injectable formulation may require additional clinical or bridging work.

Alternative oral dosage forms

An oral solution, suspension or sprinkle product may not fit a simple generic substitution strategy. The sponsor could need a 505(b)(2) application or another regulatory pathway depending on the formulation, reference product and proposed labeling.

Which companies are challenging or competing with Zemplar?

Competition comes from several groups:

• manufacturers of generic paricalcitol capsules;
• manufacturers of generic paricalcitol injection;
• AbbVie or its successor commercial arrangements for the branded product;
• alternative vitamin D receptor activators;
• dialysis providers using formulary substitution;
• products based on doxercalciferol, calcitriol or other management strategies for secondary hyperparathyroidism.

The principal competitive pressure is generic price erosion. The strongest differentiated competitors will likely be those with reliable sterile injectable capacity, integrated API sourcing, national wholesaler access and dialysis-center contracts.

How does Zemplar compare with competing vitamin D therapies?

Product class	Main advantage	Main limitation	Excipient opportunity
Paricalcitol	Established CKD use and multiple dosage forms	Generic price pressure; injectable solvent burden	Low-solvent injection and flexible oral dosing
Calcitriol	Familiar and widely available	Greater calcium and phosphorus management concerns in some settings	Improved oral liquid stability and dosing
Doxercalciferol	Alternative vitamin D analog	Narrower commercial footprint in some markets	Capsule manufacturing and unit-dose packaging
Calcimimetics	Different mechanism and strong PTH control	Different adverse-effect and cost profile	Taste masking, oral liquid delivery and adherence formats

A paricalcitol follow-on product should compete on total treatment-system cost, not only acquisition price. In dialysis settings, administration time, preparation steps, inventory reliability and dosing errors can influence formulary decisions.

What generic launch risks exist for paricalcitol?

The principal risks are operational:

• failure to achieve capsule content uniformity at microgram dose levels;
• dissolution differences caused by lipid vehicle or gelatin-shell changes;
• precipitation or phase separation in an injectable;
• solvent-related tolerability concerns;
• extractables and leachables from the container;
• inadequate stability under temperature excursions;
• sterile manufacturing interruptions;
• limited access to paricalcitol API;
• dependence on dialysis-provider contracts;
• rapid price erosion after multiple generic approvals.

A differentiated formulation should be tested against commercial realities. A technically superior excipient system has limited value if it increases manufacturing cost, requires new clinical studies or cannot support a competitive tender price.

What licensing and partnership opportunities exist?

The most credible licensing opportunities are downstream of the active ingredient:

1. API and formulation supply. A manufacturer with paricalcitol API capacity could license a capsule or injectable platform to regional generic companies.
2. Sterile fill-finish. A ready-to-use paricalcitol injection could be partnered with a contract manufacturer that already supplies dialysis centers.
3. Device-enabled delivery. Prefilled syringes, low-dead-volume systems and barcode-enabled packaging could support hospital contracts.
4. Pediatric formulation. A sponsor could license an oral liquid or flexible-dose platform to a nephrology-focused company.
5. Regional market access. Local partners could address excipient restrictions, gelatin requirements, tender rules and country-specific registration.
6. Co-development of lower-solvent formulations. This is the most technically differentiated option but also carries the highest regulatory risk.

AbbVie’s public financial reporting does not generally identify Zemplar as a separately reported revenue line. Revenue exposure should therefore be modeled through product-level sales data, prescription claims, tender awards and generic-entry assumptions rather than company-wide disclosures (AbbVie, 2024).

What geographic markets offer the best opportunity?

The United States offers the clearest abbreviated-approval framework but also the greatest generic price pressure. Europe and other regulated markets may offer opportunities for:

• gelatin-free capsules;
• country-specific colorant compliance;
• preservative or solvent preferences;
• hospital tender supply;
• localized sterile fill-finish;
• pediatric formulations.

Emerging markets may prioritize low acquisition cost and dependable availability. The main barrier is not necessarily patent protection but regulatory registration, API quality, pharmacopoeial compliance, cold-chain or sterile-manufacturing capability, and local procurement access.

Key Takeaways

• Zemplar is paricalcitol, an established small-molecule treatment for CKD-related secondary hyperparathyroidism.
• The original patent and exclusivity barriers are no longer the main commercial constraints.
• Capsule opportunity centers on microgram-dose uniformity, lipid-fill stability, gelatin performance and low-cost manufacturing.
• Injectable opportunity centers on reducing solvent burden, improving ready-to-use handling and strengthening container-closure performance.
• A pediatric oral liquid or flexible-dose product could create the clearest unmet formulation niche.
• Biosimilar risk does not apply because paricalcitol is a small molecule.
• Paragraph IV risk depends on the current Orange Book record and any later-listed formulation or method patents.
• The most defensible commercial advantage is likely to come from sterile supply reliability, dialysis-center contracts, device integration and manufacturing know-how.
• Zemplar revenue is not generally disclosed as a standalone line item by AbbVie, so product-level exposure requires market and tender data.

FAQs

Is Zemplar still protected by composition-of-matter patents?

The original composition and market exclusivity periods are no longer the central barriers to generic paricalcitol entry. Current Orange Book records should control any filing-specific patent analysis.

Can paricalcitol be reformulated as an oral solution?

Yes, but an oral solution would require control of low-dose assay accuracy, dose-device performance, stability, microbial quality, taste and adsorption. The regulatory pathway may differ from a conventional capsule ANDA.

What is the main excipient risk in paricalcitol injection?

The main risks are solvent-system tolerability, precipitation, container compatibility, extractables and leachables, and sterile manufacturing control.

Are Zemplar capsule excipients suitable for vegetarian or gelatin-free markets?

The branded soft-gelatin architecture is not inherently suitable for gelatin-free requirements. A substitute shell would require comparative testing for moisture transfer, mechanical integrity, dissolution and stability.

Could a ready-to-use paricalcitol syringe obtain premium pricing?

Potentially, if it reduces preparation steps, dosing errors, waste or administration time. The commercial case would depend on device cost, reimbursement, procurement contracts and demonstrated workflow savings.

References

1. AbbVie Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. AbbVie.

2. U.S. Food and Drug Administration. (2023a). Zemplar (paricalcitol) capsules: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023b). Zemplar (paricalcitol) injection: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.